Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIα and drug responsiveness

Molecular Pharmacology

Volumn 79, Issue 4, 2011, Pages 735-741

  Chen, Cheng Fen ^a   He, Xiaolong ^a   Arslan, Ahmet Dirim ^d   Mo, Yin Yuan ^b   Reinhold, William C ^c   Pommier, Yves ^c   Beck, William T ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d National Cancer Institute ^*

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE 2ALPHA; MICRORNA; MICRORNA 485 3P; NUCLEAR FACTOR; NUCLEAR FACTOR YB; TENIPOSIDE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME REGULATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LYMPHATIC LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RHABDOMYOSARCOMA; UPREGULATION;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CCAAT-BINDING FACTOR; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MICRORNAS; TENIPOSIDE; UP-REGULATION;

EID: 79953021596     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.069633     Document Type: Article

References (38)

1. Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, Minvielle S, Bataille R, and Intergroupe Francophone du Myélome (2002) Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 99:2185-2191.
2. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297.
3. Beck WT (1996) DNA topoisomerases and tumor cell resistance to their inhibitors, in Principles of Antineoplastic Drug Development and Pharmacology (Shilsky R, Milano G, and Ratain M eds) pp 487-502, M. Dekker, New York.
4. Bhat UG, Raychaudhuri P, and Beck WT (1999) Functional interaction between human topoisomerase IIalpha and retinoblastoma protein. Proc Natl Acad Sci USA 96:7859-7864. (Pubitemid 29328372)
5. Bhattacharya A, Deng JM, Zhang Z, Behringer R, de Crombrugghe B, and Maity SN (2003) The B subunit of the CCAAT box binding transcription factor complex (CBF/NF-Y) is essential for early mouse development and cell proliferation. Cancer Res 63:8167-8172. (Pubitemid 37549464)
6. Bourguignon LY, Spevak CC, Wong G, Xia W, and Gilad E (2009) Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to downregulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem 284:26533-26546.
7. Calin GA and Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857-866. (Pubitemid 44629897)
8. Carrington JC and Ambros V (2003) Role of microRNAs in plant and animal development. Science 301:336-338. (Pubitemid 36877060)
9. Champoux JJ (1990) Mechanistic aspects of type-II topoisomerases, in DNA Topology and Its Biological Effects (Cozzarelli NZ and Wang JC eds) pp 217-242, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
10. Chung TD, Drake FH, Tan KB, Per SR, Crooke ST, and Mirabelli CK (1989) Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci USA 86:9431-9435. (Pubitemid 20010440)
11. Danks MK, Schmidt CA, Cirtain MC, Suttle DP, and Beck WT (1988) Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27:8861-8869. (Pubitemid 19008203)
12. Esquela-Kerscher A and Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6:259-269.
13. Grady WM, Parkin RK, Mitchell PS, Lee JH, Kim YH, Tsuchiya KD, Washington MK, Paraskeva C, Willson JK, Kaz AM, et al. (2008) Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene 27:3880-3888. (Pubitemid 351862055)
14. Hu Q and Maity SN (2000) Stable expression of a dominant negative mutant of CCAAT binding factor/NF-Y in mouse fibroblast cells resulting in retardation of cell growth and inhibition of transcription of various cellular genes. J Biol Chem 275:4435-4444. (Pubitemid 30094687)
15. Kusumoto H, Rodgers QE, Boege F, Raimondi SC, and Beck WT (1996) Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II. Cancer Res 56:2573-2583. (Pubitemid 26171683)
16. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351-375.
17. Magan N, Szremska AP, Isaacs RJ, and Stowell KM (2003) Modulation of DNA topoisomerase II alpha promoter activity by members of the Sp (specificity protein) and NF-Y (nuclear factor Y) families of transcription factors. Biochem J 374:723-729. (Pubitemid 37163917)
18. Manni I, Mazzaro G, Gurtner A, Mantovani R, Haugwitz U, Krause K, Engeland K, Sacchi A, Soddu S, and Piaggio G (2001) NF-Y mediates the transcriptional inhibition of the cyclin B1, cyclin B2, and cdc25C promoters upon induced G2 arrest. J Biol Chem 276:5570-5576.
19. Melo SA, Ropero S, Moutinho C, Aaltonen LA, Yamamoto H, Calin GA, Rossi S, Fernandez AF, Carneiro F, Oliveira C, et al. (2009) A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet 41:365-370.
20. Meng F, Wehbe-Janek H, Henson R, Smith H, and Patel T (2008) Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 27:378-386.
21. Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GS, Banerjee D, and Bertino JR (2007) A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci USA 104:13513-13518. (Pubitemid 47293976)
22. Morgan SE and Beck WT (2001) Role of an inverted CCAAT element in human topoisomerase IIalpha gene expression in ICRF-187-sensitive and -resistant CEM leukemic cells. Mol Pharmacol 59:203-211. (Pubitemid 32108551)
23. Morgan SE, Cadena RS, Raimondi SC, and Beck WT (2000) Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses. Mol Pharmacol 57:296-307. (Pubitemid 30084506)
24. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
25. Nitiss JL (2009a) DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 9:327-337.
26. Nitiss JL (2009b) Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9:338-350.
27. Nitiss JL and Beck WT (1996) Antitopoisomerase drug action and resistance. Eur J Cancer 32A:958-966.
28. Pommier Y, Leo E, Zhang H, and Marchand C (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 17:421-433.
29. Ronchi A, Bellorini M, Mongelli N, and Mantovani R (1995) CCAAT-box binding protein NF-Y (CBF, CP1) recognizes the minor groove and distorts DNA. Nucleic Acids Res 23:4565-4572. (Pubitemid 126003254)
30. Roschke AV, Tonon G, Gehlhaus KS, McTyre N, Bussey KJ, Lababidi S, Scudiero DA, Weinstein JN, and Kirsch IR (2003) Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 63:8634-8647. (Pubitemid 38064038)
31. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, and Jones PA (2006) Specific activation of microRNA-127 with downregulation of the protooncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9:435-443. (Pubitemid 43832188)
32. Shankavaram UT, Varma S, Kane D, Sunshine M, Chary KK, Reinhold WC, Pommier Y, and Weinstein JN (2009) CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics 10:277.
33. Suzuki T, Yokota J, Mugishima H, Okabe I, Ookuni M, Sugimura T, and Terada M (1989) Frequent loss of heterozygosity on chromosome 14q in neuroblastoma. Cancer Res 49:1095-1098. (Pubitemid 19074818)
34. To KK, Zhan Z, Litman T, and Bates SE (2008) Regulation of ABCG2 expression at the 3′ untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol Cell Biol 28:5147-5161.
35. Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Whang-Peng J, Knutsen T, Huebner K, Croce CM, and Wang JC (1988) Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci USA 85:7177-7181.
36. Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430-440.
37. Wu H, Zhu S, and Mo YY (2009) Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res 19:439-448.
38. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, Liang S, Naylor TL, Barchetti A, Ward MR, et al. (2006) microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 103:9136-9141. (Pubitemid 43902545)